<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679742</url>
  </required_header>
  <id_info>
    <org_study_id>PSSMAR 2015/6288/I</org_study_id>
    <nct_id>NCT02679742</nct_id>
  </id_info>
  <brief_title>Postacute Sarcopenia: Supplementation With β-hydroxyMethylbutyrate After Resistance Training</brief_title>
  <acronym>PSSMAR</acronym>
  <official_title>The PSSMAR Study (Postacute Sarcopenia, Supplementation With β-hydroxyMethylbutyrate After Resistance Training)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, parallel study to assess the effects of&#xD;
      β-hydroxymethylbutyrate (β-HMB) combined with a resistance training program, after an acute&#xD;
      process in older patients with sarcopenia in terms of muscle mass, muscle strength and&#xD;
      physical performance. Treatments compared will be β-hydroxymethylbutyrate (β-HMB) with a&#xD;
      resistance training program or placebo with a resistance training program.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcopenia is a geriatric syndrome characterized by the loss of skeletal muscle mass and&#xD;
      strength that occurs with advancing age; it is related to frailty, falls, worsening quality&#xD;
      of life, and death in chronic and elderly patients. Diagnosis of sarcopenia is based on&#xD;
      clinical criteria: presence of low muscle mass and the presence of low muscle function and/or&#xD;
      low physical performance. The latest developments indicate that dietary supplementation&#xD;
      combined with resistance exercise could be an option to improve muscle mass and function.&#xD;
&#xD;
      The objective of the study is to assess the effects of β-hydroxymethylbutyrate (β-HMB)&#xD;
      combined with a resistance training program, after an acute process in older patients with&#xD;
      sarcopenia in terms of muscle mass, muscle strength and physical performance.&#xD;
&#xD;
      Design: A randomized, double-blind, placebo-controlled, parallel study with two intervention&#xD;
      groups. The investigators shall compare placebo against an intervention with β-HMB in&#xD;
      patients performing a resistance training program after an acute process (post-acute period)&#xD;
      during 12 weeks. There will be 16 patients in each arm of the study. Additionally a one year&#xD;
      follow up visit will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">February 6, 2021</completion_date>
  <primary_completion_date type="Actual">February 6, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline handgrip strength at 12 weeks</measure>
    <time_frame>From baseline till 12 weeks</time_frame>
    <description>Handgrip strength will be measured by a hand-held dynamometer (JAMAR®, Nottinghamshire, UK) and expressed in Kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline physical performance-gait speed- at 12 weeks</measure>
    <time_frame>From baseline till 12 weeks</time_frame>
    <description>Physical performance will be assessed with gait speed in the 4-m walk test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline physical performance-SPPB- at 12 weeks</measure>
    <time_frame>From baseline till 12 weeks</time_frame>
    <description>Physical performance will be assessed with gait speed in short physical performance battery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hospital readmissions</measure>
    <time_frame>From baseline till 12 weeks</time_frame>
    <description>Admissions in acute care due to medical health issues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline functional status at 12 weeks</measure>
    <time_frame>From baseline till 12 weeks</time_frame>
    <description>Functional status assessed by the Barthel index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute functional gain in 12 weeks</measure>
    <time_frame>From baseline till 12 weeks</time_frame>
    <description>Absolute functional gain measured with Barthel scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative functional gain in 12 weeks</measure>
    <time_frame>From baseline till 12 weeks</time_frame>
    <description>Relative functional gain measured with Barthel scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline rehabilitation impact indices at 12 weeks</measure>
    <time_frame>From baseline till 12 weeks</time_frame>
    <description>Rehabilitation Efficiency Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>From baseline till 12 weeks</time_frame>
    <description>Adverse events will be collected by medical interview during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline lean and fat body mass (muscle mass) at 12 weeks</measure>
    <time_frame>From baseline till 12 weeks</time_frame>
    <description>Lean and fat body mass will be measured by electrical impedance measured in kg and expressed as normal, low or high values according to normality values for the European population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>β-hydroxymethylbutyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin 3 grams once a day combined with a resistance training program</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>β-hydroxymethylbutyrate</intervention_name>
    <description>β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks</description>
    <arm_group_label>β-hydroxymethylbutyrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female ≥60 years old&#xD;
&#xD;
          -  sarcopenia diagnosis and case-finding criteria following European Working Group On&#xD;
             Sarcopenia in Older People (EWGSOP)&#xD;
&#xD;
          -  being discharged from post-acute care geriatric unit for rehabilitation treatment&#xD;
&#xD;
          -  ambulatory prior to the recent acute process&#xD;
&#xD;
          -  cognitive situation that let them to understand and follow an active physical&#xD;
             rehabilitation program (Mini-Mental Status Examination ≥21/30)&#xD;
&#xD;
          -  voluntary participation and being able and willing to provide an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  potential participants will be excluded if they have active malignancy (exception&#xD;
             basal or squamous cell skin carcinoma or carcinoma in situ of the uterine cervix)&#xD;
&#xD;
          -  major lower limb surgery over the past 6 months (knee or hip arthroplasty)&#xD;
&#xD;
          -  contraindication for resistance training&#xD;
&#xD;
          -  performed regular exercise in the last 6 months&#xD;
&#xD;
          -  use of any medications interfering with the nutritional intervention&#xD;
&#xD;
          -  serious clinical conditions that compromises and endanger the patient's life&#xD;
&#xD;
          -  contraindication, intolerance or allergy to β-hydroxymethylbutyrate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Dolores Sánchez-Rodríguez, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parc de Salut Mar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de l'Esperanza</name>
      <address>
        <city>Barcelona</city>
        <zip>09024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Sánchez-Rodríguez D, Marco E, Ronquillo-Moreno N, Miralles R, Mojal S, Vázquez-Ibar O, Escalada F, Muniesa JM. The PSSMAR study. Postacute sarcopenia: Supplementation with β-hydroxyMethylbutyrate after resistance training: Study protocol of a randomized, double-blind controlled trial. Maturitas. 2016 Dec;94:117-124. doi: 10.1016/j.maturitas.2016.08.019. Epub 2016 Sep 9.</citation>
    <PMID>27823730</PMID>
  </reference>
  <reference>
    <citation>Reginster JY, Beaudart C, Al-Daghri N, Avouac B, Bauer J, Bere N, Bruyère O, Cerreta F, Cesari M, Rosa MM, Cooper C, Cruz Jentoft AJ, Dennison E, Geerinck A, Gielen E, Landi F, Laslop A, Maggi S, Prieto Yerro MC, Rizzoli R, Sundseth H, Sieber C, Trombetti A, Vellas B, Veronese N, Visser M, Vlaskovska M, Fielding RA. Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clin Exp Res. 2021 Jan;33(1):3-17. doi: 10.1007/s40520-020-01663-4. Epub 2020 Jul 31. Review.</citation>
    <PMID>32737844</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Rodríguez D, Marco E, Miralles R, Guillén-Solà A, Vázquez-Ibar O, Escalada F, Muniesa JM. Does gait speed contribute to sarcopenia case-finding in a postacute rehabilitation setting? Arch Gerontol Geriatr. 2015 Sep-Oct;61(2):176-81. doi: 10.1016/j.archger.2015.05.008. Epub 2015 May 29.</citation>
    <PMID>26051706</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Rodríguez D, Marco E, Miralles R, Fayos M, Mojal S, Alvarado M, Vázquez-Ibar O, Escalada F, Muniesa JM. Sarcopenia, physical rehabilitation and functional outcomes of patients in a subacute geriatric care unit. Arch Gerontol Geriatr. 2014 Jul-Aug;59(1):39-43. doi: 10.1016/j.archger.2014.02.009. Epub 2014 Mar 1.</citation>
    <PMID>24726179</PMID>
  </reference>
  <reference>
    <citation>Sanchez-Rodriguez D, Marco E, Cruz-Jentoft AJ. Defining sarcopenia: some caveats and challenges. Curr Opin Clin Nutr Metab Care. 2020 Mar;23(2):127-132. doi: 10.1097/MCO.0000000000000621. Review.</citation>
    <PMID>31789867</PMID>
  </reference>
  <reference>
    <citation>Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. 2019 Jul 1;48(4):601.</citation>
    <PMID>30312372</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Rodríguez D, Marco E, Dávalos-Yerovi V, López-Escobar J, Messaggi-Sartor M, Barrera C, Ronquillo-Moreno N, Vázquez-Ibar O, Calle A, Inzitari M, Piotrowicz K, Duran X, Escalada F, Muniesa JM, Duarte E. Translation and Validation of the Spanish Version of the SARC-F Questionnaire to Assess Sarcopenia in Older People. J Nutr Health Aging. 2019;23(6):518-524. doi: 10.1007/s12603-019-1204-z.</citation>
    <PMID>31233072</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>beta hydroxy beta methylbutyrate</keyword>
  <keyword>older people</keyword>
  <keyword>muscle mass</keyword>
  <keyword>muscle strength</keyword>
  <keyword>post-acute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

